The committee reviewed background documents and evaluation reports pertaining to CIRM, including Proposition 71 and Senate Bill (SB) 1064; 2004 Economic Impact Analysis reports; the 2006 CIRM Scientific Strategic Plan; CIRM annual reports from 2007 through 2010; the 2008 Interim Economic Impact Review and addendum; the 2009 Strategic Plan Update; the 2009 Little Hoover Commission Review of CIRM; 2010 External Advisory Panel (EAP) evaluation reports; the 2011 CIRM publication on the economic impact of research funded by CIRM; and the 2012 CIRM transition plan. The committee also reviewed published reports on stem cell research.
DATA REQUESTS TO CIRM
The committee made a total of 79 requests for data, reports, and information from CIRM. These requests were on topics related to CIRM’s initial processes and planning, grants and programs, grant management and resources, reviews and evaluations, governance and management, finances, collaborations, intellectual property policies, and conflict of interest policies.
The committee hosted three public meetings to obtain additional information on specific aspects of the study charge. These meetings were held in conjunction with the committee’s October (Washington, DC), January (San Francisco, California), and April (Irvine, California) meetings. The committee determined the topics and speakers for these public meetings. As part of the two public meetings in California, the committee held open forums at which members of the public were invited to provide testimony on any topics related to the study charge.
At the first public meeting, CIRM delivered the charge to the committee and provided a general overview of its structure and programs. At the second meeting, representatives from CIRM’s leadership and governing board provided information on the Institute’s scientific priorities and transition plan, standards working group, and intellectual property policies. In addition, CIRM principal investigators provided their perspectives on the Institute. The third public meeting included presentations from individuals with varying perspectives on CIRM—investigators who applied for but did not receive funding from the Institute, current Disease Team grantees, industry representatives, and a technology transfer officer. The agendas for the public meetings are presented in Boxes A-1 through A-3.